top of page
TT3A logo.png

Trans-catheter treatment of ascending aorta aneurysms (TT3A)


TT3A S.r.l. is developing the first on-label structural heart medical device to treat patients with ascending aorta aneurisms. Current surgical treatments of this pathology result in up to an 80% mortality rate. Therefore, our primary objective is to reduce mortality, and hospitalization time.  
Complete website coming soon. 
External venture of


Contact Antonello Fazio (CEO):

About & Subscribe
bottom of page